Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;11(15):2137-48.
doi: 10.2217/fon.15.120.

Development of PROSTVAC immunotherapy in prostate cancer

Parminder Singh  1 , Sumanta K Pal  2 , Anitha Alex  3 , Neeraj Agarwal  3
Affiliations

Development of PROSTVAC immunotherapy in prostate cancer

Parminder Singh et al. Future Oncol. 2015.

Abstract

PROSTVAC immunotherapy is a heterologous prime-boost regimen of two different recombinant pox-virus vectors; vaccinia as the primary immunotherapy, followed by boosters employing fowlpox, to provoke immune responses against prostate-specific antigen. Both vectors contain transgenes for prostate-specific antigen and a triad of T-cell costimulatory molecules (TRICOM). In a placebo-controlled Phase II trial of men with minimally symptomatic, chemotherapy-naive metastatic castration-resistant prostate cancer, PROSTVAC was well tolerated and associated with a 44% reduction in death. With a novel mechanism of action, and excellent tolerability, PROSTVAC has the potential to dramatically alter the treatment landscape of prostate cancer, not only as a monotherapy, but also in combination with other novel agents, such as immune check point inhibitors and novel androgen receptor blockers. A Phase III trial recently completed accrual.

Keywords: PROSTVAC; pox virus immunotherapy; prostate cancer.

PubMed Disclaimer

Figures

Figure 1
Figure 1. PROSTVAC mechanism of action
PSA: Prostate-specific antigen; TAA: Tumor-associated antigen; TRICOM: Triad of T-cell costimulatory molecules. Figure was provided by Bavarian Nordic, Inc., Mountain View, CA, USA.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. - PubMed
    1. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419–424. - PubMed
    1. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–1520. - PubMed
    1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–1512. - PubMed
    1. Agarwal N, Padmanabh S, Vogelzang NJ. Development of novel immune interventions for prostate cancery. Clin Genitourin Cancer. 2012;10(2):84–92. - PubMed

MeSH terms